BridgeBio Pharma BBIO Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total cost of revenue?
- BridgeBio Pharma (BBIO) reported total cost of revenue of $9.94M in Q1 2026.
- How has BridgeBio Pharma's total cost of revenue changed year-over-year?
- BridgeBio Pharma's total cost of revenue increased by 276.6% year-over-year, from $2.64M to $9.94M.
- What is the long-term trend for BridgeBio Pharma's total cost of revenue?
- Over 4 years (2021 to 2025), BridgeBio Pharma's total cost of revenue has grown at a 66.4% compound annual growth rate (CAGR), from $2.74M to $20.96M.
- What does total cost of revenue mean?
- The direct costs incurred to produce and deliver the goods or services sold by the company.
- How do you interpret total cost of revenue?
- A lower ratio relative to revenue indicates higher production efficiency and better gross margins.
- How does total cost of revenue compare across companies?
- Varies significantly based on whether the company manufactures in-house or uses contract manufacturing organizations.